

ORGANIZED BY:



ENDORSED AND SUPPORTED BY:




NAMOBICA 2012

Scientific meeting:
New Approaches to Molecular Biology of Cancer
Oviedo, 2012 November 9 th

Cluster of Biomedicine and Health
University of Oviedo

www.cei.uniovi.es - clusterbms@uniovi.es
T. +34 985 10 38 32

Free REGISTRATION



Venue

Edificio Severo Ochoa (Salón de actos) Campus de "El Cristo"
Universidad de Oviedo c/Fernando Bonguera s/n, 33006 Oviedo, Spain



NAMOBICA 2012

NAMOBICA is a joint initiative of the company EntreChem Technologies and the IUOPA (University Institute of Oncology of Asturias), supported by the Cluster of Biomedicine and Health of the University of Oviedo.

The second edition of NAMOBICA offers a series of conferences, followed by science discussion forums, led by outstanding researchers devoted to the study of cancer biology and the molecular changes underlying the disease.

This edition will highlight some new trends in cancer research, beyond genomics, including implications in clinical translation and in the development of personalized medical treatment strategies.



SCIENTIFIC COMMITTEE

Carlos Suárez Nieto, Head of the Head and Neck Cancer group of the University Institute of Oncology of the Principality of Asturias (IUOPA).

Carlos López Otín, Professor of Biochemistry and Molecular Biology at the University of Oviedo, Head of the Cancer Molecular Biology research group of IUOPA.

Mario Fernández Fraga, Tenured Scientist at the National Centre of Biotechnology (CNB-CSIC), Head of the Epigenetics of Cancer research group of IUOPA.

Francisco Morís Varas, Cofounder and Managing Director of EntreChem Technologies.



ORGANIZATION AND REGISTRATION:

Cluster of Biomedicine and Health, University of Oviedo
<http://cei.uniovi.es/biomedicina>
Mail : clusterbms@uniovi.es
T : . + 34 985 10 38 32



PROGRAMME

08:45 REGISTRATION AND WELCOME RECEPTION

09:00 OPENING CEREMONY

SESSION 1: Challenges of Drug Discovery at the Post-genomic Era

09:15 **Guisseppina Carbone**
Institute of Oncology Research , IOR. Bellinzona, Switzerland
ETS transcription factors and NF-kB activation in prostate cancer: new rationale for context-dependent therapeutic strategies.

10:00 **Patrick J. Grohar**
Vanderbilt University School of Medicine. Nashville, TN, USA
Prospects and Challenges for Small Molecule Therapies Targeting Specific Transcription Factors: Development and Clinical Translation of EWS-FLI1 Inhibitors for the Treatment of Ewing Sarcoma.

10:45 **Alberto Ocaña**
Hospital General de Albacete. Spain
Problems in translational research and drug development.

11:30 ROUND TABLE DISCUSSION. Chairman: **Francisco Morís Varas**

12:00 COFFEE BREAK

SESSION 2: Recent Breakthroughs in Chronic Lymphocytic Leukemia

12:30 **Andrew Ramsay**
Universidad de Oviedo. Spain
Integrative genomics for the identification and validation of novel cancer gene in Chronic Lymphocytic Leukemia.

13:15 **Ignacio Martín Subero**
Universidad de Barcelona. Spain
Cancer Epigenomes: deciphering the DNA methylome of Chronic Lymphocytic Leukemia.

14:00 ROUND TABLE DISCUSSION. Chairman: **Mario F. Fraga**

14:30 END